Company intelligence / Profile preview

Transgene Tasly Biopharmaceutical

Tianjin, Tianjin, China

Ownership: Private
Development stage: Other

Overview

The company has conducted clinical trials for T101 (TG1050) in chronic hepatitis B, demonstrating safety and immunogenicity. T301 (TG6002) is currently in early-to-mid stage clinical trials for advanced solid tumors, focusing on its ability to selectively replicate in tumor cells and express therapeutic genes.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Oncolytic virus therapyVaccineViral vectorBiologic
Industry: Biotech

Partnerships

TransgeneTasly Pharmaceutical

Beyond the preview

Go deeper on Transgene Tasly Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transgene Tasly Biopharmaceutical.

Explore the full profile